1. Academic Validation
  2. Exploration of Alternative Scaffolds for P2Y14 Receptor Antagonists Containing a Biaryl Core

Exploration of Alternative Scaffolds for P2Y14 Receptor Antagonists Containing a Biaryl Core

  • J Med Chem. 2020 Sep 10;63(17):9563-9589. doi: 10.1021/acs.jmedchem.0c00745.
Young-Hwan Jung 1 Jinha Yu 1 Zhiwei Wen 1 Veronica Salmaso 1 Tadeusz P Karcz 2 3 Ngan B Phung 1 Zhoumou Chen 4 Sierra Duca 1 John M Bennett 1 Steven Dudas 1 Daniela Salvemini 4 Zhan-Guo Gao 1 Donald N Cook 2 Kenneth A Jacobson 1
Affiliations

Affiliations

  • 1 Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, United States.
  • 2 Immunity, Inflammation, and Disease Laboratory, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, Durham, North Carolina 27709, United States.
  • 3 Jagiellonian University, Kraków31-007, Poland.
  • 4 Department of Pharmacology and Physiology and the Henry and Amelia Nasrallah Center for Neuroscience, Saint Louis University School of Medicine, 1402 South Grand Boulevard, Saint Louis, Missouri 63104, United States.
Abstract

Various heteroaryl and bicyclo-aliphatic analogues of zwitterionic biaryl P2Y14 receptor (P2Y14R) antagonists were synthesized, and affinity was measured in P2Y14R-expressing Chinese hamster ovary cells by flow cytometry. Given this series' low water solubility, various polyethylene glycol derivatives of the distally binding piperidin-4-yl moiety of moderate affinity were synthesized. Rotation of previously identified 1,2,3-triazole attached to the central m-benzoic acid core (25) provided moderate affinity but not indole and benzimidazole substitution of the aryl-triazole. The corresponding P2Y14R region is predicted by homology modeling as a deep, sterically limited hydrophobic pocket, with the outward pointing piperidine moiety being the most flexible. Bicyclic-substituted piperidine ring derivatives of naphthalene antagonist 1, e.g., quinuclidine 17 (MRS4608, IC50 ≈ 20 nM at hP2Y14R/mP2Y14R), or of triazole 2, preserved affinity. Potent antagonists 1, 7a, 17, and 23 (10 mg/kg) protected in an ovalbumin/Aspergillus mouse asthma model, and PEG conjugate 12 reduced chronic pain. Thus, we expanded P2Y14R antagonist structure-activity relationship, introducing diverse physical-chemical properties.

Figures